Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
1. Ascendis Pharma presents new data at ASBMR 2025 in Seattle. 2. Key findings include improvements in children’s leg bowing and physical function. 3. Long-term data shows sustained skeletal improvements in hypoparathyroidism adults. 4. The studies strengthen Ascendis' growth disorder treatment portfolio potential. 5. Executives emphasize the significance of TransCon technology in patient care.